尾加压素II受体调节剂作为潜在药物。 - Suppr

Urotensin-II receptor modulators as potential drugs.

作者信息

Maryanoff Bruce E, Kinney William A

机构信息

Johnson & Johnson Pharmaceutical Research & Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776, USA.

出版信息

J Med Chem. 2010 Apr 8;53(7):2695-708. doi: 10.1021/jm901294u.

DOI:10.1021/jm901294u

PMID:20043680

Abstract

摘要

相似文献

Urotensin-II receptor modulators as potential drugs.尾加压素II受体调节剂作为潜在药物。

J Med Chem. 2010 Apr 8;53(7):2695-708. doi: 10.1021/jm901294u.

Identification of new agonists of urotensin-II from a cyclic peptide library.

Bioorg Med Chem. 2009 Sep 15;17(18):6742-7. doi: 10.1016/j.bmc.2009.07.058. Epub 2009 Jul 28.

Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.人尿紧张素II受体的三维模型：人尿紧张素II和非肽拮抗剂在结合位点的对接以及与拮抗剂药效团模型的比较

Proteins. 2008 Oct;73(1):173-84. doi: 10.1002/prot.22050.

Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.非肽类尾加压素II受体激动剂和拮抗剂：综述与构效关系

Peptides. 2008 May;29(5):680-90. doi: 10.1016/j.peptides.2007.09.019. Epub 2007 Oct 6.

Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor.

Peptides. 2009 Jun;30(6):1130-6. doi: 10.1016/j.peptides.2009.02.003. Epub 2009 Feb 12.

Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.P5U 和尿抑肽先导化合物优化：在 UII 受体发现新型强效配体。

J Med Chem. 2014 Jul 24;57(14):5965-74. doi: 10.1021/jm500218x. Epub 2014 Jul 10.

Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor.人尿紧张素受体强效无胱氨酸环六肽激动剂的设计与合成

Org Lett. 2006 Apr 27;8(9):1799-802. doi: 10.1021/ol060278h.

Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.用光标记尾加压素II受体可揭示不同的激动剂和部分激动剂结合位点。

Biochem J. 2007 Feb 15;402(1):51-61. doi: 10.1042/BJ20060943.

[Urotensin II and cardiac disease].[尾加压素 II 与心脏疾病]

Nihon Rinsho. 2004 Sep;62 Suppl 9:722-6.

Urotensin-II receptor peptide agonists.尾加压素 II 受体肽激动剂

Med Res Rev. 2004 Sep;24(5):577-88. doi: 10.1002/med.20001.

引用本文的文献

Combination of Docking-Based and Pharmacophore-Based Virtual Screening Identifies Novel Agonists That Target the Urotensin Receptor.基于对接和基于药效团的虚拟筛选相结合，鉴定靶向尾加压素受体的新型激动剂。

Molecules. 2022 Dec 8;27(24):8692. doi: 10.3390/molecules27248692.

Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action.对参与尿调节素和尿调节素A作用的分子决定因素的见解。

ACS Med Chem Lett. 2020 Aug 20;11(9):1717-1722. doi: 10.1021/acsmedchemlett.0c00223. eCollection 2020 Sep 10.

Targeting of G-protein coupled receptors in sepsis.脓毒症中 G 蛋白偶联受体的靶向治疗。

Pharmacol Ther. 2020 Jul;211:107529. doi: 10.1016/j.pharmthera.2020.107529. Epub 2020 Mar 19.

Urotensin-#receptor antagonist SB-706375 protected isolated rat heart from ischaemia-reperfusion injury by attenuating myocardial necrosis via RhoA/ROCK/RIP3 signalling pathway.尿皮质素受体拮抗剂 SB-706375 通过衰减 RhoA/ROCK/RIP3 信号通路减轻心肌坏死从而保护分离的大鼠心脏免受缺血再灌注损伤。

Inflammopharmacology. 2019 Dec;27(6):1309-1318. doi: 10.1007/s10787-019-00598-1. Epub 2019 Jun 5.

Palosuran treatment effective as bosentan in the treatment model of pulmonary arterial hypertension.帕罗苏兰治疗在肺动脉高压治疗模型中与波生坦同样有效。

Inflammation. 2014 Aug;37(4):1280-8. doi: 10.1007/s10753-014-9855-8.

The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.《2013/14药理学简明指南：G蛋白偶联受体》

Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445.

Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.关于尿皮质素系统的最新研究进展：受体定位、激活及药物设计的新趋势。

Front Endocrinol (Lausanne). 2013 Jan 2;3:174. doi: 10.3389/fendo.2012.00174. eCollection 2012.

Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.旨在区分 UII 和 URP 介导的生物学活性的新型拮抗剂的发现：对 UII 和 URP 受体激活的深入了解。

Br J Pharmacol. 2013 Feb;168(4):807-21. doi: 10.1111/j.1476-5381.2012.02217.x.

Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart.大鼠心脏中核尿皮质素-II 结合位点的生化和药理学特征。

Br J Pharmacol. 2012 May;166(1):243-57. doi: 10.1111/j.1476-5381.2011.01710.x.

GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.GSK1562590，一种缓慢解离的尾加压素 II 受体拮抗剂，在体外表现出延长的药效动力学活性。

Br J Pharmacol. 2010 Sep;161(1):207-28. doi: 10.1111/j.1476-5381.2010.00889.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Urotensin-II receptor modulators as potential drugs.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献